Doma Perpetual Capital Management LLC Boosts Position in InMode Ltd. $INMD

Doma Perpetual Capital Management LLC increased its position in InMode Ltd. (NASDAQ:INMD) by 26.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,838,431 shares of the healthcare company’s stock after buying an additional 599,108 shares during the quarter. InMode accounts for approximately 14.2% of Doma Perpetual Capital Management LLC’s holdings, making the stock its 4th biggest holding. Doma Perpetual Capital Management LLC’s holdings in InMode were worth $42,293,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its holdings in InMode by 93.7% in the 3rd quarter. Blue Trust Inc. now owns 2,861 shares of the healthcare company’s stock worth $43,000 after acquiring an additional 1,384 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of InMode during the third quarter valued at about $52,000. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of InMode during the third quarter worth about $69,000. Rothschild Investment LLC purchased a new stake in shares of InMode during the third quarter worth about $85,000. Finally, Topline Capital Management LLC bought a new stake in shares of InMode in the second quarter worth about $160,000. 68.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on INMD shares. Canaccord Genuity Group set a $15.00 price target on InMode and gave the company a “hold” rating in a report on Wednesday, December 17th. BTIG Research reiterated a “neutral” rating on shares of InMode in a research report on Monday, January 26th. Weiss Ratings reissued a “sell (d+)” rating on shares of InMode in a research note on Thursday, January 22nd. Finally, Robert W. Baird set a $17.00 target price on InMode in a report on Wednesday, February 11th. One research analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $16.80.

InMode Price Performance

Shares of NASDAQ INMD opened at $13.54 on Monday. InMode Ltd. has a 1 year low of $12.72 and a 1 year high of $19.09. The stock has a market capitalization of $857.89 million, a P/E ratio of 9.40 and a beta of 2.18. The company’s 50-day moving average is $14.40 and its 200 day moving average is $14.63.

InMode (NASDAQ:INMD) last issued its quarterly earnings data on Tuesday, February 10th. The healthcare company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.42 by $0.04. The business had revenue of $103.85 million during the quarter, compared to analyst estimates of $104.64 million. InMode had a net margin of 25.33% and a return on equity of 14.52%. InMode’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same period last year, the business posted $0.42 earnings per share. Research analysts anticipate that InMode Ltd. will post 1.75 earnings per share for the current year.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.